Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Core Viewpoint - Valneva SE's chikungunya vaccine IXCHIQ has been recommended for a pause in use for individuals aged 65 and over by the FDA and CDC due to ongoing investigations into serious adverse events [1][3]. Company Summary - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [8]. - The company has a strong track record of advancing multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [9]. - Valneva is committed to maintaining high safety standards and has proactively engaged with health authorities regarding reported serious adverse events related to IXCHIQ [2][4]. Vaccine and Safety Information - The FDA and CDC have recommended the use of IXCHIQ for individuals aged 18 to 60 years, while the EMA recommends it for individuals aged 12 to 64 years [5]. - Over 40,000 doses of IXCHIQ have been administered worldwide, with most serious adverse events reported in elderly individuals with significant underlying medical conditions [3][5]. - Valneva continues to monitor adverse events, particularly from the chikungunya vaccination campaign in La Réunion, where no further serious adverse events have been reported outside this public vaccination effort [4]. Chikungunya Overview - Chikungunya is a mosquito-borne viral disease that has caused significant outbreaks globally since 2004, with over 3.7 million cases reported in the Americas between 2013 and 2023 [6][7]. - The World Health Organization has identified chikungunya as a major public health problem, with the economic impact expected to grow due to climate change [7].